HOSPIRA INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | $99.6M | −$118.6M | $58.8M | $56.8M | $519.2M | $502.9M |
| Net income | — | — | — | — | $141.7M | $165.5M |
| Total assets | $6.65B | $6.18B | $6.09B | $5.78B | $6.05B | $5.50B |
| Total liabilities | — | — | — | — | — | — |
| Equity | $3.34B | $2.96B | $3.04B | $2.94B | $3.18B | $2.62B |
| EPS (diluted) | $0.40 | $-0.46 | $0.27 | $-0.06 | $2.11 | $2.47 |
| Shares out. | 166.5M | 165.4M | 164.7M | 166.6M | 163.9M | 163.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- —
- Return on capital (ROCE)
- 1.9%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $20.04
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 good- Positive operating cash flow
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- BENDAMUSTINE HYDROCHLORIDEDec 15, 2022
- PEMETREXED DITROMETHAMINEJun 10, 2022
- BUSULFANJul 31, 2018
- ARGATROBANSep 21, 2016
- INDOMETHACIN SODIUMApr 19, 2016
- SODIUM BICARBONATEMar 4, 2016
- LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERJun 18, 2015
- ZOLEDRONIC ACIDMar 19, 2015
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ramachandra SumantOfficer — SVP & Chief Scientifc Ofcr | Sep 3, 2015 | D | 271 | $90.00 |
| Yoskowitz Marc JOfficer — SVP, Strategy & Corporate Dev | Sep 3, 2015 | Grant | 3,640 | $0.00 |
| Werner Thomas EOfficer — SVP, Finance & CFO | Sep 3, 2015 | Option exercise | 664.74 | — |
| Stober Matthew ROfficer — SVP, Operations | Sep 3, 2015 | Option exercise | 2,323.279 | — |
| Kaufman Zena G.Officer — SVP, Quality | Sep 3, 2015 | Grant | 8,435 | $0.00 |
| Hoffman Richard JOfficer — CVP, Controller & CAO | Sep 3, 2015 | Grant | 4,826 | $0.00 |
| Smith Brian JOfficer — SVP and Special Counsel | Sep 3, 2015 | D | 9,706.975 | $90.00 |
| Ball F MichaelOfficer — Chief Executive Officer | Sep 3, 2015 | Grant | 36,691 | $0.00 |
| Meyers Kenneth FOfficer — SVP, Chief Human Resources Ofr | Sep 3, 2015 | Grant | 8,997 | $0.00 |
| Gendron MaryOfficer — SVP, Chief Information Officer | Sep 3, 2015 | Option exercise | 290.031 | — |
| Endicott David J.Officer — Pres., Hospira Medical Devices | Sep 3, 2015 | Grant | 15,196 | $0.00 |
| Davies Richard JohnOfficer — SVP, Chief Commercial Officer | Sep 3, 2015 | Grant | 9,173 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsSep 3, 2015
- Other material eventAug 27, 2015
- Results of operationsJul 29, 2015
- Other material eventJun 24, 2015
- Shareholder voteMay 13, 2015
- Shareholder voteMay 12, 2015
- Results of operationsApr 28, 2015
- Other material eventApr 7, 2015
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BFORM 15-12BOct 6, 2015
- 15-12BFORM 15Sep 14, 2015
- 4FORM 4 -Sep 3, 2015
- S-8 POSSep 3, 2015
- S-8 POSSep 3, 2015
- S-8 POSSep 3, 2015
- S-8 POSSep 3, 2015
- S-8 POSSep 3, 2015
- S-8 POSSep 3, 2015
- S-8 POSSep 3, 2015
- POSASRSep 3, 2015
- 8-KHOSPIRA, INC. 8-KSep 3, 2015
- 4FORM 4 -Sep 3, 2015
- 4FORM 4 -Sep 3, 2015
- 4FORM 4 -Sep 3, 2015
Corporate family
Spun off from Abbott LaboratoriesABT · Apr 29, 2004
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.